M&A

News

Recordati gets €10.9bn takeover bid from private equity firm

Recordati has received a takeover offer from private equity group CVC that, if completed, would delist it from the Italian stock exchange.

News

Novartis snaps up food allergy firm Excellergy for $2bn

Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.

News

Update: Rumour confirmed as MSD buys Terns for $6.7bn

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7bn bid to acquire Terns Pharma.

News

Gilead buys autoimmune disease biotech Ouro for $2.2bn

Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.

News

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

News

Veeva buys brand engagement firm Ostro for $100m

Veeva Systems has reached a $100m deal to acquire Ostro, which helps pharma connect with doctors and patients using AI-based conversational tools.

Recordati gets €10.9bn takeover bid from private equity firm

Novartis snaps up food allergy firm Excellergy for $2bn

Update: Rumour confirmed as MSD buys Terns for $6.7bn

Gilead buys autoimmune disease biotech Ouro for $2.2bn

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Veeva buys brand engagement firm Ostro for $100m

AZ's gMG drug Klygefa nears EU approval

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks